Home › Esophageal Adenocarcinoma › Georgia
Esophageal Adenocarcinoma clinical trials in Georgia
5 studies for Esophageal Adenocarcinoma are looking for participants at sites in Georgia.
Cities in Georgia
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Emory Saint Joseph's Hospital, Atlanta
- and 2 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT06203600mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
- Tift Regional Medical Center, Tifton
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT05677490A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- Emory University, Atlanta
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07221149Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Research Site, Atlanta
- Research Site, Atlanta
- Research Site, Macon
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT07431281A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
- Winship Cancer Center - Emory University, Atlanta
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 15, 2026 · NCT06657144From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.